Qianru Wu1, Xuanyi Li1,2, Yan Sha3, Chunfu Dai4. 1. Department of Otology and Skull Base Surgery, Hearing Research Key Lab of Health Ministry of China, Eye and Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China. 2. Department of Otolaryngology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. 3. Department of Radiology, Eye and Ear Nose and Throat Hospital, Fudan University, Shanghai, China. 4. Department of Otology and Skull Base Surgery, Hearing Research Key Lab of Health Ministry of China, Eye and Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China. cfdai66@163.com.
Abstract
PURPOSE: The aims of the present study are to investigate the variations in clinical features, including medical history, hearing function, vestibular function, and degree of endolymphatic hydrops (EH), in Meniere's disease (MD) patients with and without drop attacks (DAs), and to examine the efficacy of intratympanic gentamicin (ITG) treatment in alleviating DAs. METHODS: In total, 177 unilateral definite MD patients, including 16 patients with DAs and 161 patients without DAs, were enrolled. The results of hearing test, vestibular-evoked myogenic potentials (VEMPs), and magnetic resonance imaging (MRI) were analyzed. Thirteen patients with DAs received a single ITG treatment and were followed up. RESULTS: The disease course of MD in the DA group was significantly longer than that in the control group (p = 0.007). MD patients with DAs had significantly greater hearing loss and worse EH than MD patients without DAs (p < 0.05). However, there was no between-group difference in vestibular function. In the study, 92.31% of refractory definite MD patients with DAs achieved satisfactory control of DAs after ITG treatment. CONCLUSIONS: MD patients with DAs tend to suffer from severe hearing loss and a significant degree of EH in the inner ear. However, the vestibular function of MD patients with DAs may not be completely abolished, but be sensitive to stimulating signals. ITG treatment, which helps to decrease vestibular sensitivity, was an effective treatment to control DAs.
PURPOSE: The aims of the present study are to investigate the variations in clinical features, including medical history, hearing function, vestibular function, and degree of endolymphatic hydrops (EH), in Meniere's disease (MD) patients with and without drop attacks (DAs), and to examine the efficacy of intratympanic gentamicin (ITG) treatment in alleviating DAs. METHODS: In total, 177 unilateral definite MD patients, including 16 patients with DAs and 161 patients without DAs, were enrolled. The results of hearing test, vestibular-evoked myogenic potentials (VEMPs), and magnetic resonance imaging (MRI) were analyzed. Thirteen patients with DAs received a single ITG treatment and were followed up. RESULTS: The disease course of MD in the DA group was significantly longer than that in the control group (p = 0.007). MD patients with DAs had significantly greater hearing loss and worse EH than MD patients without DAs (p < 0.05). However, there was no between-group difference in vestibular function. In the study, 92.31% of refractory definite MD patients with DAs achieved satisfactory control of DAs after ITG treatment. CONCLUSIONS: MD patients with DAs tend to suffer from severe hearing loss and a significant degree of EH in the inner ear. However, the vestibular function of MD patients with DAs may not be completely abolished, but be sensitive to stimulating signals. ITG treatment, which helps to decrease vestibular sensitivity, was an effective treatment to control DAs.
Authors: S Iwasaki; L A McGarvie; G M Halmagyi; A M Burgess; J Kim; J G Colebatch; I S Curthoys Journal: Neurology Date: 2007-04-10 Impact factor: 9.910
Authors: Ferdinand C A Timmer; Guangwei Zhou; John J Guinan; Sharon G Kujawa; Barbara S Herrmann; Steven D Rauch Journal: Laryngoscope Date: 2006-05 Impact factor: 3.325
Authors: Roulla Katiri; Deborah A Hall; Nora Buggy; Nicholas Hogan; Adele Horobin; Paul van de Heyning; Jill B Firszt; Iain A Bruce; Pádraig T Kitterick Journal: Trials Date: 2020-03-04 Impact factor: 2.279